Used for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.
The ability of pimozide to suppress motor and phonic tics in Tourette's Disorder is thought to be primarily a function of its dopaminergic blocking activity. Pimozide binds and inhibits the dopamine D2 receptor in the CNS.
LD<sub>50</sub> = 1100 mg/kg (rat, oral), 228 mg/kg (mouse, oral)
Greater than 50% absorption after oral administration. Serum peak appears 6-8 hours post ingestion.
29 &plusmn; 10 hours (single-dose study of healthy volunteers).